• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cytokinetics Starts Phase 2 Clinical Trial for Cardiomyopathy Treatment

    Danielle Edwards
    Jan. 07, 2020 03:30PM PST
    Pharmaceutical Investing
    NASDAQ:CYTK

    The company said its myosin inhibitor will be evaluated to optimize its dosing schedule to a therapeutic window for patients with HCM.

    Cytokinetics (NASDAQ:CYTK) is moving forward into a Phase 2 clinical trial for a next-generation treatment of hypertrophic cardiomyopathy (HCM).

    The company said on Monday (January 6) that its drug CK-3773274 (CK-274), a cardiac myosin inhibitor, will be evaluated to optimize its dosing schedule to a refined therapeutic window associated with positive outcomes for patients dealing with the condition.

    The study, titled REDWOOD-HCM, will be designed as a randomized, placebo-controlled, double-blind clinical trial in patients with symptomatic, obstructive HCM.

    Since the start of the trading session on Monday, Cytokinetics has risen 2.9 percent and was sitting at US$11.15 as of 2:49 p.m. EST.

    HCM is an inherited cardiovascular disorder that thickens the heart muscle, shrinking the left ventricle and obstructing blood flow to the heart. Patients have been found to suffer from chest pain, fainting and a higher risk of arrhythmias, stroke, heart failure and sudden cardiac death.

    Myosins are a family of proteins that play a role in muscle contractions, among other motility processes, and myosin inhibitors can help induce muscle relaxation.

    In a statement, Fady I. Malik, Cytokinetics’ executive vice president of research and development, said the second stage of the trial will quickly follow the release of its Phase 1 data.

    Malik added that the first phase of testing found that the cardiac myosin inhibitor achieved the intended effects and reached steady state drug movement throughout the body within 14 days, allowing for a two week dosing regimen.

    The California-based biopharmaceutical company said that during preclinical models of cardiac function, the drug was successful in reducing myocardial contractility in a dose- and exposure-dependent fashion.

    Now, the newest trial will enroll two groups of 18 patients each, with the option for a third. The groups will randomly receive either a placebo or three escalating doses of CK-274 over the course of 10 weeks, and will get echocardiograms every two weeks during the testing period.

    Currently, there aren’t any treatments that address the excessive thickening of the heart muscle that underlies HCM, according to the company.

    In the statement, Marty Maron, director of the Hypertrophic Cardiomyopathy Center and the principal investigator of REDWOOD-HCM, highlighted the importance of the treatment for patients dealing with symptoms of HCM that decrease their quality of life.

    Analyst consensus on TipRanks has Cytokinetics listed as a moderate buy with a target price of US$22.67, representing a 103.7 percent upside over its current share price.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

    nasdaq:cytkpharmaceutical investingphase 2 clinical trial
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×